US DoD declines option for further supply of Valneva's JE vaccine

22 August 2022

French speciality vaccines maker Valneva (Nasdaq: VALN) has announced that the US Department of Defense (DoD) has decided not to exercise the second option year of the contract to supply Valneva’s Japanese encephalitis (JE) vaccine Ixiaro.

Due to the past and ongoing impact of the COVID-19 pandemic on its operations, the DoD considers its existing Ixiaro supply levels sufficient to meet current needs. The DoD has communicated an interest in negotiating a new supply contract in 2023, once inventory returns to standard levels.

Valneva expects no impact on its 2022 financial guidance as a result of this decision and will continue deliveries of Ixiaro under the terms of the first option year, which the DoD exercised with amended terms, through the fourth quarter of 2022. The DoD has relied on Ixiaro since 2010 to help protect personnel who are deployed to JE endemic areas, for whom JE vaccination is recommended.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK